#ALS Press Releases

The new short film LAYERS explores the emotional depths of living with ALS

The new short film LAYERS explores the emotional depths of living with ALS

Preproduction has begun on the short comedy-drama LAYERS from Angry Bee Films and producers Graham Jones, Martina Avogadri and Fay Beck, who also writes and directs. Samera Entertainment invites you to help bring this important story to the screen. The…

First Patient Treated With ILB in TIKOMED's Clinical Trial for ALS

First Patient Treated With ILB in TIKOMED's Clinical Trial for ALS

TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for treating acute and degenerative neurological diseases, announce today that the first patient with Amyotrophic Lateral Sclerosis (ALS) has been treated with the company’s investigational drug ILB, in the on-going clinical…

Tikomed to Initiate ALS Clinical Trial for Which the UK Medicines and Healthcare Products Regulatory Agency Has Granted Permission

TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases, has been granted permission by the UK Medicines and Healthcare products Regulatory Agency, for a phase II clinical trial of the company’s…

Tikomed Granted Permission for Clinical Trial in ALS by the Swedish Medical Product Agency and Ethical Review Board.

​TikoMed, a specialty pharmaceutical company focused on developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases, is delighted to announce that the company has been granted permission for a clinical trial (Phase 2a) in ALS (Amyotrophic Lateral Sclerosis)…

Fortuna Fix annonce le financement de séries B, ajoutant Amgen Ventures et le gestionnaire de patrimoine Macnguyen parmi ses actionnaires

Fortuna Fix annonce le financement de séries B, ajoutant Amgen Ventures et le gestionnaire de patrimoine Macnguyen parmi ses actionnaires

​​​​​​​​​​​​La société privée Fortuna Fix (“Fortuna”) basée au Centre Québécois d'Innovation en Biotechnologie (CQIB) et INRS-Institut Armand Frappier à Laval, se concentre sur la Médecine Régénérative et est plus précisément spécialisée dans la production de cellules souches neurales autologues (du patient…

Fortuna Fix Announces Series B Financing, Adding Amgen Ventures and Macnguyen Family Office as Shareholders

Fortuna Fix Announces Series B Financing, Adding Amgen Ventures and Macnguyen Family Office as Shareholders

Fortuna Fix (“Fortuna”), a private, clinical-stage Regenerative Medicine company is aiming to be the first to bring to the clinic a patient’s own neural stem cells (autologous) produced by direct reprogramming (“drNPCs”) to replace lost neuronal tissue in neurodegeneration and neurotrauma. Fortuna announces…

Simplesa® is Now Offering the Deanna Protocol® and Lunasin to ALS Patients

Simplesa® is Now Offering the Deanna Protocol® and Lunasin to ALS Patients

Patients with ALS (PALS) have been following the Deanna Protocol (DP) since it was first released in 2011. The Deanna Protocol is an all-natural metabolic program developed by Dr. Vincent Tedone, a retired physician whose daughter, Deanna, was diagnosed with…

Shamrock Financial Proud Title Sponsor of the 2017 ALS Charity Golf Tournament

Shamrock Financial Proud Title Sponsor of the 2017 ALS Charity Golf Tournament

Shamrock Financial was the proud title sponsor of the 22nd annual golf tournament for the Rhode Island chapter of the ALS association.The ALS golf tournament raises funds for the Rhode Island chapter of the Amyotrophic Lateral Sclerosis (ALS) Association. ALS…

St Lucie Mets Second Annual ALS Awareness Game

St Lucie Mets Second Annual ALS Awareness Game

The first pitch will be in honor of local Port St Lucie resident, Chris R. Carr. 30 year old newlywed, who was diagnosed with ALS last February 2016. He has huge support group from his family, friends and employer. Chris…

Major Hospital Accounces Another FDA clinical trial for ALS/Lou Gehrigs Patients and L-Serine

A major Los Angeles hospital announced another clinical trial of l-serine for ALS/Lou Gehrigs disease patients. This will be the 3rd clinical trial of l-serine, a natural amino acid, for patients with Amyotrophic Lateral Sclerosis. There is clinical evidence that…

The Deanna Protocol® Continues to Impress ALS Patients

The Deanna Protocol® Continues to Impress ALS Patients

​​It was just a few years ago that the Ice Bucket Challenge caught everyone's eye and raised awareness for ALS, or Lou Gehrig 's disease. At the time the Deanna Protocol® was relatively new but it was already helping many…

Improving Quality of Life for ALS Patients is a Growing Trend for Simplesa®'s Deanna Protocol™

Improving Quality of Life for ALS Patients is a Growing Trend for Simplesa®'s Deanna Protocol™

ALS is an incurable disease, and the last year has seen some monumental medical and scientific strides to finding a cure.  In the interim, many patients with amyotrophic lateral sclerosis (PALS) are faced with deteriorating health, progressive symptoms and a…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login